Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
30
Sab, Mag

Abbiamo 2944 visitatori e nessun utente online

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening 

HOUSTON, May 19, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to announce the launch of its

innovative XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery. 

XPressMAX™ Cell-Free Protein Synthesis Kit 

The novel kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies—eliminating the constraints of traditional cell-based expression systems. By seamlessly integrating with AI-powered screening platforms, the kit helps researchers accelerate the identification and optimization of antibody candidates, reducing both development timelines and costs. 

Based on an E. coli lysate and fully supplemented with essential transcription and translation components, XPressMAX™ enables direct protein synthesis from plasmid or PCR templates. Designed for antibody drug discovery, XPressMAX™ enables rapid expression and validation of VHH, scFv, Fab, and Miniprotein. Leveraging XPressMAX™, Sino Biological has established a high-throughput cell-free platform that validates 2,000+ scFv/VHH molecules in 3–4 weeks, matching AI's rapid iteration. 

XPressMAX™ Highlights 

"Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. "By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality." 

"AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput," said Dr. Jie Zhang, Sino Biological's General Manager. "XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours." 

Researchers can visit www.sinobiological.com to explore more about XPressMAX™ or click here to request a free sample. 

About Sino Biological 

Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech (part of Sino Biological) in Canada, Sino Biological delivers tailored, localized solutions to meet diverse research needs worldwide. Serving researchers in over 90 countries, the company maintains a stringent quality management system for all products. 

Sino Biological, Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo. www.sinobiological.com  

Photo - https://mma.prnewswire.com/media/2982956/1200_1200.jpg  

View original content:https://www.prnewswire.co.uk/news-releases/sino-biological-launches-xpressmax-cell-free-protein-synthesis-kit-accelerating-ai-powered-high-throughput-antibody-drug-discovery-302775798.html  

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall'ente che lo emette. L'Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

Author: RedWebsite: http://ilcentrotirreno.it/Email: Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.